Post-Treatment PET Scans Can Reassure Cervical Cancer Patients

Whole-body positron emission tomography (PET) scans performed three months after completion of cervical cancer therapy can ensure that patients are disease-free or warn that further interventions are needed, according to new research.

"This is the first time we can say that we have a reliable test to follow cervical cancer patients after therapy,” stated Julie K. Schwarz, M.D., Ph.D., a Barnes-Jewish Hospital resident in the department of radiation oncology at Washington University School of Medicine in St. Louis (MO, USA). "We ask them to come back for a follow-up visit about three months after treatment is finished, and we perform a PET scan. If the scan shows a complete response to treatment, we can say with confidence that they are going to do extremely well. That's really powerful.”

Dr. Schwarz and colleagues published their findings in the November 21, 2007 issue of the Journal of the American Medical Association (JAMA). Without an imaging modality like PET, it can be difficult to tell whether treatment has eliminated cervical tumors, according to Dr. Schwarz. The reason is because small tumors are hard to identify with pelvic exams, and overt symptoms, such as leg swelling, do not occur until tumors grow quite large. Moreover, computed tomography (CT) and magnetic resonance imaging (MRI) scans frequently do not differentiate tumor tissue from surrounding tissues, Pap tests can be inaccurate because of tissue changes induced by radiation therapy, and no blood test as of yet exists to detect the presence of cervical cancer.

Cancerous tumors glow brightly in the PET scans used in the study, called fluorodeoxyglucose- (FDG)-PET scans, which detect emissions from radioactively tagged blood sugar, or glucose. Tumor tissue captures more of the glucose than does normal tissue, making tumors readily discernable.

Not only can post-treatment PET scans reassure those patients whose tumors respond well to therapy, they can also identify those patients whose tumors have not responded so that their physicians can explore other treatment alternatives before the cancer advances further. These options can include surgery to remove tissue, standard chemotherapy, or experimental therapies available through clinical trials.

"Follow-up PET scans can also be very useful tools for physicians conducting clinical trials of new therapies,” Dr. Schwarz noted. "Our study has shown that the scans are predictive of long-term survival. Using PET scans, clinical researchers can get an early readout of how effective experimental treatments might be.”

Dr. Schwarz and colleagues also have initiated a study to compare follow-up PET results with tumor biology to find out why some tumors do not respond well to therapy. In that study, she found differences in gene activity between tumors from patients that responded well and those that had persistent disease. Ongoing research will look for the significance of these differences.

The study's senior author, Perry Grigsby, M.D., professor of radiation oncology, department of nuclear medicine and of obstetrics and gynecology and a radiation oncologist with the Siteman Cancer Center at Washington University School of Medicine, has overseen a patient database that now has PET images and tumor samples from hundreds of cervical cancer patients.

"We have a tremendous database of PET images collected from patients in the department since 1998,” Dr. Schwarz stated. "We want to combine these results with analyses of tumor biopsies so that we can more effectively choose additional therapies for patients who haven't responded to the initial treatment.”


Related Links:
Washington University